PetMed Express, Inc.

  • Market Cap: Micro Cap
  • Industry: Retailing
  • ISIN: US7163821066
USD
1.73
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About PetMed Express, Inc. stock-summary
stock-summary
PetMed Express, Inc.
Retailing
PetMed Express, Inc. (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies. Its products include brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution and Rimadyl. It also offers additional pet supplies for sale on its Website, which are drop shipped to its customers by third parties. These pet supplies include food, beds, crates, stairs, strollers and other pet supplies. Its products included Non-Prescription Medications (Over the Counter (OTC)) and supplies, and Prescription Medications (Rx). Its customers are located in California, Florida, Texas, New York, Virginia and Georgia, among others.
Company Coordinates stock-summary
Company Details
420 S Congress Ave , DELRAY BEACH FL : 33445-4693
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 44 Schemes (49.46%)

Foreign Institutions

Held by 72 Foreign Institutions (8.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Robert Schweitzer
Independent Chairman of the Board
Mr. Menderes Akdag
President, Chief Executive Officer, Director
Ms. Leslie Campbell
Independent Director
Mr. Frank Formica
Independent Director
Dr. Gian Fulgoni
Independent Director
Mr. Ronald Korn
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
53 Million
(Quarterly Results - Dec 2024)
Net Profit:
-1 Million
stock-summary
Industry

Retailing

stock-summary
Market cap

USD 59 Million (Micro Cap)

stock-summary
P/E

82.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.52

stock-summary
Return on Equity

0.29%

stock-summary
Price to Book

0.61